A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

This was the stock's third consecutive day of gains.

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

Vertex Global Services partners with Arish Global Services to create 5,000 jobs in Delhi-NCR, focusing on business process ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Fintel reports that on January 3, 2025, Raymond James downgraded their outlook for Vertex (NasdaqGM:VERX) from Outperform to ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...